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Abstract Recently, there has been a paradigm shift away
from an emphasis on the role of the endocrine (circulating)
renin-angiotensin system (RAS) in the regulation of the
sodium and extracellular ﬂuid balance, blood pressure, and
the pathophysiology of hypertensive organ damage toward
a focus on the role of tissue RAS found in many organs,
including kidney. A tissue RAS implies that RAS compo-
nents necessary for the production of angiotensin II (Ang
II) reside within the tissue and its production is regulated
within the tissue, independent of the circulating RAS.
Locally produced Ang II plays a role in many physiological
and pathophysiological processes such as hypertension,
inﬂammation, oxidative stress, and tissue ﬁbrosis. Both
glomerular and tubular compartments of the kidney have
the characteristics of a tissue RAS. The purpose of this
article is to review the recent advances in tissue RAS
researchwith a particular focus on the role of the glomerular
RAS in the progression of renal disease.
Keywords Renin-angiotensin system  Angiotensin II 
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Introduction
Since the discovery of kidney renin by Tigerstedt and
Bergman [1], the renin-angiotensin system (RAS) has
been established as an endocrine (circulating) system that
plays a role in several organs to maintain the sodium and
extracellular ﬂuid balance, and thereby regulate blood
pressure (BP). Angiotensin II (Ang II) is the most powerful
biological product of this system and its action is trans-
mitted by two main G-protein-coupled receptors with
seven-transmembrane domains—Ang II type 1 receptor
and type 2 receptor (AT1R and AT2R). Recently, the
landscape of this system has become more complex with
the discovery of new peptides, new proteins, new enzy-
matic pathways, new functions of RAS, and a tissue Ang
II-generating system, a so-called ‘local’ or ‘tissue’ RAS,
that acts at the tissue level in a paracrine and autocrine
manner [2, 3]. A growing body of evidence from clinical
and experimental studies has further highlighted the role
that the tissue RAS plays in various disease conditions such
as hypertension, inﬂammation, oxidative stress and tissue
ﬁbrosis in many organs [4–7]. It is now well known that the
kidney contains all of the elements of the RAS, and locally
produced Ang II contributes to not only kidney ontogeny
but also to the regulation of BP and progression of chronic
kidney disease (CKD) [6–8]. The objective of this review is
to explain the role of the renal tissue RAS, with particular
focus on the role of the glomerular RAS in disease pro-
gression based on recent data. The presence and role of the
tubular RAS in the kidney have been extensively reviewed
by Kobori et al. [7] and will not be discussed here.
Recent advances in RAS biology
Traditionally, the circulating RAS is known to regulate BP,
sodium balance and ﬂuid homeostasis (Fig. 1). Brieﬂy,
renin (protease) secreted from the granular cells of the
juxtaglomerular apparatus reacts with angiotensinogen
(AGT) produced by the liver to release Ang I (1–10), which
is further cleaved by a dipeptidyl carboxypeptidase,
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capillary endothelial cells of the lung, to convert Ang I to
Ang II (1–8). Ang II is considered the major physiologi-
cally active component of RAS. The biological actions of
Ang II are transmitted by two seven-transmembrane
G-protein-coupled receptors—AT1R and AT2R. Most of
the physiological effects of Ang II are conveyed by AT1R.
AT1R activation induces an increase in blood volume and
BP by stimulating vasoconstriction, along with adrenal
aldosterone secretion, renal sodium reabsorption and
sympathetic neurotransmission. This classical view of the
RAS has been signiﬁcantly expanded by more recent
ﬁndings that increased the complexity of the system [9,
10]. Ang II is now considered to play a role in cell pro-
liferation, hypertrophy, superoxide production, inﬂamma-
tion and extracellular matrix (ECM) production through the
induction of cytokines, chemokines and growth factors
[11]. Furthermore, accumulating evidence indicates that
other biologically active peptides [Ang (1–7), Ang III and
Ang IV] besides Ang II are generated via the activity of
ACE2, a homolog of ACE, and several peptidases such as
neprilysin (NEP), aminopeptidase A (AP-A) and AP-N.
ACE2 is a monocarboxypeptidase that catalyzes the con-
version of Ang I to ng (1–9) or the conversion of Ang II to
Ang (1–7). The action of Ang (2–10) derived from Ang I via
AP-A is still not deﬁnitively characterized, but has been
implicated in the modulation of vasopressor responses in
hypertensive rats [12]. Additionally, new receptors such as
Mas receptor, AT4R and prorenin/renin receptor (PRR)
have been identiﬁed [13–15]. The binding of prorenin to
PRR leads to the activation of prorenin to active renin by
displacement of the prosegment. Interestingly, stimulation
of the PRR activates intracellular signaling, thus upregu-
lating the expression of proﬁbrotic proteins [16]. The recent
characterization of the ACE2/Ang (1–7)/Mas receptor axis
provides a new pathway for inducing vasodilatory, anti-
proliferative, and antiﬁbrotic actions, which counteract the
classicalACE/AngII/AT1RaxisoftheRAS[17].Inparallel
with the recognition ofnew RAS components andactivation
pathways, the concept of a tissue RAS has emerged with the
support of tremendous clinical and experimental research.
The functional aspects of tissue RAS actions are based on
the tissue-based synthesis of ANG II, independent of the
circulating RAS.
Ang II as a central mediator in progressive glomerular
injury
Most CKD that progresses into renal failure begins at the
glomerulus. A relentless glomerular injury usually induces
glomerulosclerosis characterized by the massive accumu-
lation of ECM, local tuft adhesion to Bowman’s capsule
and/or crescent formation [18, 19]. Ang II has emerged as a
crucial mediator in progressive glomerular diseases
through the induction of glomerular hypertension as well as
nonhemodynamic effects that include the production of
reactive oxygen species (ROS), up-regulation of proﬁbrotic
growth factors (platelet-derived growth factor, transform-
ing growth factor-b [TGF-b], tumor necrosis factor-a), and
macrophage activation and inﬁltration [11, 20]. These
injurious actions induced by Ang II affect the behaviors of
all four types of glomerular cells [mesangial cells (MC),
endothelial cells (GEC), and visceral and parietal epithelial
cells (POD and PEC, respectively)] that are involved in
severe pathological alterations and constitute a vicious
cycle that leads to nephron loss for disease progression
(Fig. 2). Extensive studies in various human diseases and
in animal models have shown that ACE inhibitors (ACEIs)
and/or AT1R blockers (ARBs) are superior to other anti-
hypertensive agents for protecting the kidney against pro-
gressive glomerular deterioration, which supports the
concept that Ang II is a local paracrine/autocrine effector
for the progression of glomerular injury [21, 22].
Involvement of the glomerular RAS in disease
progression
A growing body of evidence demonstrates that all of the
components of the RAS are present within the glomerulus
and the resultant product, Ang II, regulates glomerular
capillary blood ﬂow and capillary wall permeability, and
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Fig. 1 Overview of the renin-angiotensin system (RAS). The
schematic shows the circulating RAS (inside the four-sided line) as
well as newly recognized enzymatic pathways that lead to the
formation and metabolism of products derived from angiotensinogen
(AGT). PRR prorenin/renin receptor, ACE angiotensin-converting
enzyme, ACE2 angiotensin-converting enzyme 2, AP-A aminopepti-
dase A, AP-N aminopeptidase N, NEP neprilysin, Ang I angiotensin I,
Ang II angiotensin II, AT1R angiotensin II type I receptor, AT2R
angiotensin II type 2 receptor, AT4R angiotensin II type 4 receptor.
Modiﬁed from Refs. [9, 10]
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123contributes to the development and progression of glomer-
ular diseases as described above. Seminal studies by Seikaly
et al. [23] with micropuncture methods showed that the
concentrations of total immunoreactive Ang (reﬂecting Ang
II and lesser amounts of three fragments) in rat glomerular
ﬁltrate averaged 32 nM compared with 32 pM in systemic
plasma, indicating that the Ang II concentration in Bow-
man’s space is 1000-fold higher than that in the systemic
circulation. They subsequently demonstrated for the ﬁrst
time that isolated rat glomeruli can produce Ang II inde-
pendent of neural innervation, vascular attachment, or
exogenous inﬂuences. These ﬁndings ﬁrmly support the
glomerulus-based synthesis of Ang II [24]. Many studies
using immunohistochemical and in situ hybridization tech-
niques have reported that RAS components such as AGT,
ACE, ACE2, Ang II, AT1R and AT2R can be detected in
normalanddiseasedglomeruliinbothratsandhumans,anda
parallel increase in AGT and Ang II, with inconsistent
ﬁndingsregarding the remaining RAS components, isseenin
diseased glomeruli from several types of glomerulopathy in
rats and humans [25–30]. In genetically manipulated ani-
mals, rat glomeruli that have been modiﬁed with the human
renin and AGT genes developed glomerular sclerosis and
showed MC activation (a-smooth muscle actin-positive)
[31]. Upstream stimulatory factor 2 transgenic mice show
increased renin expression and enhanced renin activity in the
kidney, which stimulates the generation of glomerular Ang II
which leads to glomerular hypertrophy and ECM accumu-
lation accompanied by enhanced TGF-b expression and
albuminuria [32]. Furthermore, recent biochemical analyses
of isolated glomeruli have revealed that, in diabetic rats, the
level of glomerular Ang II peptide is increased due to an
increased level of AGT protein and an increase in the for-
mation of Ang II via an unidentiﬁed enzymatic pathway that
does not involve ACE within glomeruli [33].
AGT is the only known substrate for renin, the rate-lim-
itingenzymeoftheRAS,andtheamountofAGTistherefore
an essential determinant for the amount of tissue-based Ang
II production and tissue RAS activity [7]. However, the
speciﬁc cellular origins of AGT and the activation mode of
theRASthatleadstoAngIIformationwithintheglomerulus
remain to be fully elucidated. A remarkable study by Lee
et al. using a rat remnant model reported that, as a result of
hemodynamic changes, injured or activated GEC synthe-
sizes AGT, which triggers a cascade from the glomerular
generation of Ang II–TGF-b and ECM protein gene
expression, which results in the development of segmental
glomerular sclerotic lesions [34]. This pathological pro-
gressioncanbepreventedbyARB,whichindicatesthatAng
II–AT1Rsignalingplaysacentralroleindiseaseprogression
in this rat model. We have investigated the potential role of
the glomerular Ang II–TGF-b pathway (proﬁbrotic path-
way)inpathologicalglomerularECMremodelingduringthe
progression of CKD [35–38]. Recently, we performed an
immunohistochemical analysis using renal biopsy samples
of immunoglobulin A nephropathy (IgAN) and minor glo-
merular abnormalities (MGA) that were found in the early
stage of disease by a school urinary screening system in
Japan[30].GlomerularAGTisweaklyexpressedbyGECin
MGA patients, but strongly induced at endocapillary sites
includingGECandMCinIgANpatients,althoughtheyhave
normal glomerular ﬁltration rate and BP (Fig. 3). The level
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Fig. 2 The central role of angiotensin II (RAS activation) in
progressive glomerular injury. ROS reactive oxygen species, GFs
growth factors, U macrophage, TIF tubulo-interstitial ﬁbrosis; ECM,
extracellular matrix. Modiﬁed from Refs. [18, 20]
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Fig. 3 Protein expression of angiotensinogen (AGT) in isolated
human glomeruli and immunohistochemical staining of AGT in
patients with minor glomerular abnormalities (MGA) or IgA
nephropathy (IgAN). a Western blot analysis was performed using
samples of isolated human glomeruli (lane 1) and puriﬁed human
AGT (lane 2), respectively. Anti-human AGT antibody reacted with a
61 kDa band in each sample. b In patients with MGA, AGT was
strongly expressed in proximal tubules and weakly detected in
glomerular endothelial cells. c In patients with IgAN, AGT expression
was strongly induced by glomerular endothelial cells and mesangial
cells. Modiﬁed from Ref. [30]
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123of glomerular AGT parallels the levels of glomerular Ang II
and TGF-b expression in diseased glomeruli. The level of
glomerular injury, such as cell proliferation, ECM accumu-
lation and proteinuria, is also closely correlated with the
levelsofAGTandAngII.Additionally,theAGTlevelseems
to determine the Ang II level in nephritic glomeruli. Fur-
thermore, several cell culture studies, including ours, have
shown that Ang II can stimulate AGT mRNA and AGT
protein biosynthesis by renal cells, suggesting that its action
might constitute an auto-amplifying loop of the activity of
the intrarenalRAS[7,30].Therefore,we postulate thateven
intheearlystageofIgAN,glomerularRASactivationseems
to occur as a result of increased GEC- and MC-AGT
expressionand promotes tothe enhancedlocalgenerationof
Ang II, which leads to clinical and pathological abnormali-
ties. A glomerular Ang II–AGT-positive feedback loop
might drive RAS activation for further glomerular injury.
The substantial association between glomerular RAS
activity (Ang II generation) and glomerular TGF-b, ROS
generation and pathological alterations was then investi-
gated using a rat model of crescentic glomerulonephritis
(GN)incombinationwithtreatmentwithARB(candesartan)
[39]. For the ROS-generating system, we focused on the
expression of Nox2, a major component of NAD(P)H oxi-
dase,whichiswellknowntobeamajorsourceofROSinthe
diseased kidney and is activated by Ang II stimulation [37].
Vehicle-treated nephritic rats showed signiﬁcant proteinuria
and severe crescentic nephritis while treatment with ARB
signiﬁcantly attenuated proteinuria, glomerular Ang II
accumulation, superoxide production and associated patho-
logical alterations (Fig. 4). Consistent with these histologi-
cal ﬁndings, a biochemical analysis usingisolated glomeruli
revealed that glomerular production of AGT, Ang II, and
TGF-b and Nox2 was enhanced in nephritic rats while
treatment with ARB signiﬁcantly reduced the production of
each of these in glomeruli to close to the control level
Control GN (day 28) GN+ARB (day 28)
A BC
D EF
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Fig. 4 Effects of the ARB candesartan in anti-GBM antibody-
induced nephritic rats. Nephritic rats were treated with or without
candesartan, sacriﬁced on day 28, and then subjected to an
immunohistochemical examination. Light microscopic examination
showed that severe crescentic nephritis had developed by day 28
(b) but was signiﬁcantly attenuated by treatment with ARB (c). PBS-
injected rats were used as normal control rats (a, d, g).
Immunostaining revealed that nephritic rats showed diffuse and
strong glomerular Ang II staining (e), while ARB treated-nephritic
rats showed segmental accentuated staining of Ang II (f). Control rats
showed weak positive Ang II staining (d). Strong superoxide
production (DHE dye) was detected in nephritic rats (h) compared
with control rats (g), but was signiﬁcantly attenuated in ARB treated-
nephritic rats (i). Modiﬁed from Ref. [39]
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123(Fig. 5). These results suggest that a glomerular Ang II-
generating system works in vivo and the produced Ang II
induces TGF-b expression and superoxide, and ﬁnally con-
tributes to the development of crescentic GN in rats. Simi-
larly, Nakamura et al. [40] reported that salt-sensitive
glomerular injury in eNOS-/- mice was mediated by the
enhancement of glomerular GEC-AGT-derived Ang II,
through the augmentation of glomerular oxidative stress.
Taken together, these ﬁndings suggest that GEC-AGT
expression plays a key role in glomerular RAS activation
followed by glomerular pathological alterations in CKD.
Glomerular Ang II production is also regulated by the
expression ratio of ACE to ACE2 within the glomerulus
[27]. ACE2 plays a primary role in converting Ang II to
Ang (1–7), which mediates vasodilation, antiproliferative,
and antiﬁbrotic actions via Mas receptor, and therefore has
the potential to counterbalance the effects of ACEs [17].
ACE2 is now considered to be an endogenous ACEI [41].
In the diabetic mouse and human kidney, increased ACE
expression and decreased ACE2 expression is observed in
damaged glomeruli and indicates that the glomerular
ACE/ACE2 balance plays a role in mediating glomerular
injury, possibly by increasing the glomerular accumulation
of Ang II [27, 42]. Notably, male ACE2 mutant (ACE2-/
y) mice with an increase in the renal tissue Ang II level
develop glomerulosclerosis [41]. Sensitive indicators of
ROS production, lipid peroxidation products and the glo-
merulosclerosis score were markedly enhanced in those
mice while ARB prevented these increases, which strongly
supports the notion that ACE2 plays a role in Ang
II-induced glomerular injury. More recently, a similar rela-
tionship between ACE2 and ACE expression in diseased
glomeruli was reported even in patients with IgAN [43].
New approach for the analysis of Ang peptides
generated by the glomerular RAS pathway
Since RAS is a far more complex and dynamic system than
was originally recognized, assays that are more selective,
sensitive, and rapid than conventional radioimmunoassay
and high-performance liquid chromatographic separation
of peptide products are needed for the identiﬁcation of
RAS components and peptide-enzymatic cascades in RAS.
The emergence of matrix-assisted laser desorption ioniza-
tion time of ﬂight (MALDI-TOF) mass spectrometry (MS)
allows us to clarify Ang metabolism with more speciﬁcity
and ease than with previous methods. Recently, Velez et al.
examined the metabolism of Ang I in freshly isolated intact
rat glomeruli using MALDI-TOF-MS [10, 44, 45]. They
showed that there is prominent glomerular conversion of
Ang I–Ang (2–10) and Ang (1–7), mediated by AP-A and
NEP, respectively, and suspected that the formation of
these alternative Ang peptides may be critical for count-
erbalancing the local actions of Ang II within glomeruli.
They then examined the contribution of POD or GEC to
Ang metabolism in glomerulus using MALDI-TOF-MS
in combination with cell culture methods [45, 46]. They
demonstrated that POD expressed a functional intrinsic
RAS characterized by AGT, NEP, AP-A, ACE2, and renin
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Fig. 5 Biochemical analysis of nephritic rats on day 28 with or
without treatment with ARB. Samples from isolated glomeruli from
either control rats, day 28 nephritic rats or ARB-treated day 28
nephritic rats were subjected to Western blot analysis using anti-AGT
antibody (a), Ang II measurement using ELISA (b), TGF-b
measurement using ELISA (c) and Western blot analysis using anti-
Nox2 antibody (d). Control control rats, GN nephritic rats without
ARB treatment, GN ? ARB nephritic rats with ARB treatment.
#p\0.01 versus control;
§p\0.05 versus GN; *p\0.01 versus GN.
Modiﬁed from Ref. [39]
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123activities, which predominantly lead to Ang (1–7) and Ang
(1–9) formation, as well as Ang II degradation [45]. In
contrast, GEC exhibited prominent ACE activity leading to
Ang II, with the production of less Ang (1–7) and thus a
lower degradative ability of Ang II [46], suggesting that
injury to speciﬁc cell types in the glomeruli may lead to
distinct effects on the glomerular RAS balance. In addition,
many studies have reported that MC also express a func-
tional intrinsic RAS characterized by AGT, prorenin,
cathepsin B (a potential enzyme involved in renin activa-
tion), chymase, ACE, and ACE2, which primarily gener-
ates Ang II and very small amounts of Ang (1–7) and Ang
(1–9) [45, 47, 48, 49]. Taken together, these ﬁndings
suggest that variations in glomerular cell injury and the
relative abundance of Ang I metabolites such as Ang II,
Ang (1–7), Ang (1–9) and Ang (2–10) within glomeruli
determine the net autocrine or paracrine effects of these
Ang peptides on glomerular cells. A detailed analysis of
the paramount enzymatic pathway in the RAS responsible
for the conversion to these Ang peptides may provide
therapeutic tools such as ACEIs for Ang II-mediated glo-
merular diseases.
Conclusion and future directions
There is no controversy regarding the concept that the
glomerulus-based RAS plays a role in glomerular physi-
ology and pathophysiology. Enhanced glomerular Ang II
action in diseased glomeruli via ACE/Ang II/AT1R sig-
naling promotes cell proliferation and ECM production,
and decreases ECM degradation resulting in sclerotic
lesions. Evidence in animal and human CKD has shown
that RAS blockers such as ACEIs and ARBs are an
effective and promising therapy for attenuating the pro-
gression of CKD beyond BP-lowering effect, which sup-
ports the above discussion. Several technical advances,
including the use of molecular biology, peptide chemistry
and the availability of transgenic and knock-out mice with
altered expression of RAS components, have given us a
more complex view of a glomerular RAS composed of a
variety of peptidases, Ang peptides, and receptors involved
in these Ang actions. The modulation of RAS pathways
such as ACE2/Ang (1–7)/Mas receptor and PRR might
become future therapeutic targets in CKD. Moreover, the
identiﬁcation of a glomerulus-speciﬁc enzymatic pathway
for RAS activation could lead to a therapeutic strategy for
attenuating the progression of glomerular disease in CKD.
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